NASDAQ:UTHR - United Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$125.03 +0.94 (+0.76 %)
(As of 07/22/2018 04:00 PM ET)
Previous Close$125.03
Today's Range$121.8224 - $126.64
52-Week Range$100.57 - $152.55
Volume380,738 shs
Average Volume284,285 shs
Market Capitalization$5.44 billion
P/E Ratio11.48
Dividend YieldN/A
Beta1.32
United Therapeutics logoUnited Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292

Debt

Debt-to-Equity Ratio0.11
Current Ratio5.13
Quick Ratio4.81

Price-To-Earnings

Trailing P/E Ratio11.48
Forward P/E Ratio9.59
P/E Growth31.97

Sales & Book Value

Annual Sales$1.73 billion
Price / Sales3.16
Cash Flow$12.0337 per share
Price / Cash10.39
Book Value$48.64 per share
Price / Book2.57

Profitability

EPS (Most Recent Fiscal Year)$10.89
Net Income$417.90 million
Net Margins27.74%
Return on Equity26.68%
Return on Assets19.25%

Miscellaneous

Employees800
Outstanding Shares43,540,000
Market Cap$5,444.31

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How will United Therapeutics' stock buyback program work?

United Therapeutics declared that its Board of Directors has authorized a stock buyback plan on Sunday, June 4th 2017, which authorizes the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 4.6% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board believes its shares are undervalued.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported $5.57 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.62 by $1.95. The biotechnology company had revenue of $389.20 million for the quarter, compared to analysts' expectations of $393.96 million. United Therapeutics had a net margin of 27.74% and a return on equity of 26.68%. The company's revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.61 earnings per share. View United Therapeutics' Earnings History.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for United Therapeutics.

What price target have analysts set for UTHR?

6 analysts have issued twelve-month target prices for United Therapeutics' stock. Their predictions range from $95.00 to $232.00. On average, they anticipate United Therapeutics' share price to reach $139.6667 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Ratings for United Therapeutics.

What is the consensus analysts' recommendation for United Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of United Therapeutics' key competitors?

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the folowing people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 63)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 46)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 50)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Kevin Gray, Sr. VP of Strategic Operations & Logistics

Has United Therapeutics been receiving favorable news coverage?

Media stories about UTHR stock have been trending somewhat positive on Sunday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. United Therapeutics earned a media sentiment score of 0.22 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.73 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include NN Investment Partners Holdings N.V. (0.21%), Bank of Montreal Can (0.15%), Retirement Systems of Alabama (0.13%), James Investment Research Inc. (0.05%), Empirical Finance LLC (0.04%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Which institutional investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Empirical Finance LLC, NN Investment Partners Holdings N.V., Municipal Employees Retirement System of Michigan, RDL Financial Inc. and Xact Kapitalforvaltning AB. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Judy D Olian, Martine A Rothblatt and Raymond Dwek. View Insider Buying and Selling for United Therapeutics.

Which institutional investors are buying United Therapeutics stock?

UTHR stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, James Investment Research Inc., Nisa Investment Advisors LLC, Clinton Group Inc., Assenagon Asset Management S.A., Fox Run Management L.L.C., Fjarde AP Fonden Fourth Swedish National Pension Fund and State of Alaska Department of Revenue. View Insider Buying and Selling for United Therapeutics.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $125.03.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $5.44 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]


MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  350 (Vote Outperform)
Underperform Votes:  472 (Vote Underperform)
Total Votes:  822
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.